1
Home
Companies

Dynavax Technologies

#4893

Rank

$1.34B

Marketcap

US United States

Country

Dynavax Technologies
Leadership team

Mr. Ryan Spencer (CEO & Director)

Mr. David F. Novack (Pres & COO)

Ms. Kelly MacDonald (Sr. VP & CFO)

Products/ Services
Biopharma, Biotechnology, Clinical Trials, Health Care, Medical Device
Number of Employees
100 - 500
Headquarters
Berkeley, California, United States
Established
1996
Company Registration
SEC CIK number: 0001029142
Net Income
100M - 500M
Revenue
500M - 1B
Traded as
DVAX
Social Media
URL
https://www.dynavax.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
History

Dynavax Technologies Corporation was founded as an immunology-focused company in 1997 by Michael A. Ostrakhovsky, M.D., and Hasmukh P. Wani, Ph.D. The company went public in 2005 and is traded on the NASDAQ. Dynavax has licensed a number of technologies from the University of California and other academic and biopharmaceutical companies.

Mission
Dynavax's mission is to discover, develop and commercialize innovative immunotherapies that will have a meaningful impact on patients’ lives.
Vision
At Dynavax, we are dedicated to becoming the leader in immuno-oncology and other immune-mediated indications by helping to re-educate and modulate the immune system.
Key Team

Mr. Michael S. Ostrach (Advisor)

Dr. Robert Janssen (Chief Medical Officer and Sr. VP of Clinical Devel., Medical & Regulatory Affairs)

Mr. Justin Burgess (Principal Accounting Officer & Controller)

Mr. Jeff P. Coon (CHRO and Sr. VP of HR & Admin.)

Nicole Arndt (Sr. Mang. of Investor Relations)

Mr. John Slebir (Sr. VP & Gen. Counsel)

Ms. Meg Smith (VP Sales & Operations)

Recognition and Awards
Dynavax has received numerous awards over the years, including the 2006 Annual Achievement Award from the San Francisco Chamber of Commerce and the Entrepreneur of the Year Award from Ernst & Young in 2005.
References

https://in.investing.com/equities/dynavax-tech

https://finance.yahoo.com/quote/DVAX/profile?p=DVAX

https://www.crunchbase.com/organization/dynavax-technologies

https://sec.report/CIK/0001029142

https://companiesmarketcap.com/

https://www.dynavax.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Dynavax Technologies
Leadership team

Mr. Ryan Spencer (CEO & Director)

Mr. David F. Novack (Pres & COO)

Ms. Kelly MacDonald (Sr. VP & CFO)

Products/ Services
Biopharma, Biotechnology, Clinical Trials, Health Care, Medical Device
Number of Employees
100 - 500
Headquarters
Berkeley, California, United States
Established
1996
Company Registration
SEC CIK number: 0001029142
Net Income
100M - 500M
Revenue
500M - 1B
Traded as
DVAX
Social Media
URL
https://www.dynavax.com